Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 10, 2017. The report details the announcement of headline phase III clinical trial results for mepolizumab (Nucala) as an investigational add-on treatment for adults with severe chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical update and does not contain financial statements or performance metrics.
Material Changes and Clinical Results
The filing reports preliminary results from two pivotal phase III studies (METREX and METREO) evaluating mepolizumab in COPD patients:
- Study 117106 (METREX): In the subgroup with higher blood eosinophil counts, mepolizumab 100mg demonstrated a statistically significant 18% reduction in the frequency of moderate and severe exacerbations compared to placebo (p=0.036 after multiplicity adjustment).
- Study 117113 (METREO): Evaluated mepolizumab 100mg and 300mg. While reductions in exacerbations were observed (20% for 100mg; 14% for 300mg), the results were not statistically significant (p=0.068 and p=0.140, respectively, after multiplicity adjustment).
- Safety Profile: No new safety concerns were identified. The frequency of adverse events and serious adverse events was similar between mepolizumab and placebo groups across both studies.
Outlook, Management Commentary, and Risks
Management Commentary: Steve Yancey, GSK's Vice President and Medicine Development Lead for mepolizumab, stated that the observed reductions in exacerbations are of clinical relevance for difficult-to-treat patients. Management plans to review full data to determine next steps.
Outlook: Full results will be submitted for presentation at an upcoming scientific congress and for publication in a peer-reviewed journal. Mepolizumab is not currently approved for COPD anywhere in the world but is approved as Nucala for severe eosinophilic asthma in the US, EU, and other jurisdictions.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the company's 2016 Annual Report on Form 20-F. Specific safety warnings for Nucala include hypersensitivity reactions, herpes zoster, and the need for gradual corticosteroid dose reduction.
Key Facts for Investor Verification
- Verify the statistical significance of the METREO study results (p=0.068 and p=0.140) and GSK's criteria for proceeding with regulatory filings for COPD.
- Confirm the timeline for the submission of full data to scientific congresses and peer-reviewed journals.
- Review the safety data regarding herpes zoster and hypersensitivity reactions in the context of the COPD patient population.
- Assess the potential impact of these results on GSK's respiratory portfolio valuation, given mepolizumab is not yet approved for this indication.